Kaplan–Meier survival analysis of the TCGA-LGG-GBM dataset revealed that patients with increased CKS2 expression had a worse prognosis than those with a lower expression (HR = 4.90; 95% CI: 3.67–6.55, p < 0.001, Figure 3A). This evidence concerns the gene CKS2 and glioblastoma.